Bliss GVS Pharma · NSE: BLISSGVS · BSE: 506197
Q2 FY25 results · Jul–Sep 2024
Bliss GVS Pharma reported revenue from operations of ₹217.68 crore (up 2.7% from Q2 FY24) and net profit of ₹25.69 crore (down 40.3% from Q2 FY24) for Q2 FY25 (Jul–Sep 2024), on a consolidated basis.
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 217.68 | 211.88 | +2.7% | 183.64 | +18.5% |
| Other income | 5.04 | 12.60 | −60.0% | 4.12 | +22.2% |
| Total income | 222.72 | 224.48 | −0.8% | 187.77 | +18.6% |
| Profit before tax | 35.71 | 59.13 | −39.6% | 30.07 | +18.7% |
| Net profit for the period | 25.69 | 43.04 | −40.3% | 22.11 | +16.2% |
| Attributable to shareholders of the company | 24.26 | 42.31 | −42.7% | 20.70 | +17.2% |
| EPS, basic (₹) | 2.31 | 4.06 | −43.1% | 1.97 | +17.3% |
| Net margin (%) | 11.8 | 20.3 | 12.0 |
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 182.65 | 171.32 | +6.6% | 148.96 | +22.6% |
| Other income | 8.35 | 10.61 | −21.3% | 6.84 | +22.1% |
| Total income | 191.00 | 181.93 | +5.0% | 155.80 | +22.6% |
| Profit before tax | 23.89 | 46.07 | −48.1% | 26.15 | −8.7% |
| Net profit for the period | 17.04 | 33.89 | −49.7% | 19.42 | −12.2% |
| EPS, basic (₹) | 1.63 | 3.25 | −49.8% | 1.85 | −11.9% |
| Net margin (%) | 9.3 | 19.8 | 13.0 |
Consolidated
- Filed with BSE
- 08 Nov 2024, 14:15 IST
- Board meeting
- 24 Oct 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 08 Nov 2024, 14:15 IST
- Board meeting
- 24 Oct 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE